Literature DB >> 24259517

Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.

Marzia Perluigi, Fabio Di Domenico, D Allan Buttterfield.   

Abstract

Down syndrome (DS) is one of the most common genetic causes of intellectual disability characterized by multiple pathological phenotypes, among which neurodegeneration is a key feature. The neuropathology of DS is complex and likely results from impaired mitochondrial function, increased oxidative stress, and altered proteostasis. After the age of 40 years, many (most) DS individuals develop a type of dementia that closely resembles that of Alzheimer's disease with deposition of senile plaques and neurofibrillary tangles. A number of studies demonstrated that increased oxidative damage, accumulation of damaged/misfolded protein aggregates, and dysfunction of intracellular degradative systems are critical events in the neurodegenerative processes. This review summarizes the current knowledge that demonstrates a “chronic” condition of oxidative stress in DS pointing to the putative molecular pathways that could contribute to accelerate cognition and memory decline. Proteomics and redox proteomics studies are powerful tools to unravel the complexity of DS phenotypes, by allowing to identifying protein expression changes and oxidative PTMs that are proved to be detrimental for protein function. It is reasonable to suggest that changes in the cellular redox status in DS neurons, early from the fetal period, could provide a fertile environment upon which increased aging favors neurodegeneration. Thus, after a critical age, DS neuropathology can be considered a human model of early Alzheimer's disease and could contribute to understanding the overlapping mechanisms that lead from normal aging to development of dementia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24259517      PMCID: PMC3965623          DOI: 10.1002/prca.201300066

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  129 in total

1.  Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis.

Authors:  S D Yan; H Zhu; A Zhu; A Golabek; H Du; A Roher; J Yu; C Soto; A M Schmidt; D Stern; M Kindy
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

Review 2.  The brain in Down syndrome (TRISOMY 21).

Authors:  Gert Lubec; Ephrem Engidawork
Journal:  J Neurol       Date:  2002-10       Impact factor: 4.849

Review 3.  Proteasomes: machines for all reasons.

Authors:  George N Demartino; Thomas G Gillette
Journal:  Cell       Date:  2007-05-18       Impact factor: 41.582

Review 4.  The proteasome: molecular machinery and pathophysiological roles.

Authors:  Keiji Tanaka; Tsunehiro Mizushima; Yasushi Saeki
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

Review 5.  Degradation of oxidized proteins in mammalian cells.

Authors:  T Grune; T Reinheckel; K J Davies
Journal:  FASEB J       Date:  1997-06       Impact factor: 5.191

Review 6.  Beta-amyloid, oxidative stress and down syndrome.

Authors:  Ira T Lott; Elizabeth Head; Eric Doran; Jorge Busciglio
Journal:  Curr Alzheimer Res       Date:  2006-12       Impact factor: 3.498

Review 7.  Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain.

Authors:  Rukhsana Sultana; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2012-10-05       Impact factor: 7.376

Review 8.  Recognition and processing of ubiquitin-protein conjugates by the proteasome.

Authors:  Daniel Finley
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

9.  Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease.

Authors:  Tanea Reed; Marzia Perluigi; Rukhsana Sultana; William M Pierce; Jon B Klein; Delano M Turner; Raffaella Coccia; William R Markesbery; D Allan Butterfield
Journal:  Neurobiol Dis       Date:  2008-01-05       Impact factor: 5.996

10.  Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ).

Authors:  Varaprasad Kolla; Paul Jenö; Suzette Moes; Sevgi Tercanli; Olav Lapaire; Mahesh Choolani; Sinuhe Hahn
Journal:  J Biomed Biotechnol       Date:  2009-11-05
View more
  27 in total

1.  Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Cesare Mancuso; Eugenio Barone; Francesca Paolini; Andrea Arena; Carla Blarzino; Frederick A Schmitt; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Antonella Tramutola; Alessandra Giorgi; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2014-03-25       Impact factor: 7.376

Review 3.  Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Authors:  Eugenio Barone; Andrea Arena; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2017-07-10       Impact factor: 7.376

4.  Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype.

Authors:  Antonella Tramutola; Gilda Pupo; Fabio Di Domenico; Eugenio Barone; Andrea Arena; Chiara Lanzillotta; Diede Brokeaart; Carla Blarzino; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 5.  The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.

Authors:  D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-07-01       Impact factor: 7.376

Review 6.  Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain.

Authors:  D Allan Butterfield; Fabio Di Domenico; Aaron M Swomley; Elizabeth Head; Marzia Perluigi
Journal:  Biochem J       Date:  2014-10-15       Impact factor: 3.857

Review 7.  Exosomal biomarkers in Down syndrome and Alzheimer's disease.

Authors:  Eric D Hamlett; Aurélie Ledreux; Huntington Potter; Heidi J Chial; David Patterson; Joaquin M Espinosa; Brianne M Bettcher; Ann-Charlotte Granholm
Journal:  Free Radic Biol Med       Date:  2017-09-05       Impact factor: 7.376

Review 8.  Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins.

Authors:  D Allan Butterfield; Erika M Palmieri; Alessandra Castegna
Journal:  Expert Rev Proteomics       Date:  2016       Impact factor: 3.940

9.  RCAN1 overexpression promotes age-dependent mitochondrial dysregulation related to neurodegeneration in Alzheimer's disease.

Authors:  Helen Wong; Josien Levenga; Peter Cain; Beverly Rothermel; Eric Klann; Charles Hoeffer
Journal:  Acta Neuropathol       Date:  2015-10-24       Impact factor: 17.088

Review 10.  When nature's robots go rogue: exploring protein homeostasis dysfunction and the implications for understanding human aging disease pathologies.

Authors:  Julie A Reisz; Alexander S Barrett; Travis Nemkov; Kirk C Hansen; Angelo D'Alessandro
Journal:  Expert Rev Proteomics       Date:  2018-03-21       Impact factor: 3.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.